Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 562

1.

Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.

Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, Hochhaus A, Hofmann WK, Cross NCP, Reiter A.

Blood Adv. 2020 Feb 11;4(3):440-443. doi: 10.1182/bloodadvances.2019001111.

2.

The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time?

Höllein A, Twardziok SO, Walter W, Hutter S, Baer C, Hernandez-Sanchez JM, Meggendorfer M, Haferlach T, Kern W, Haferlach C.

Cancer Genet. 2020 Jan 11. pii: S2210-7762(19)30521-6. doi: 10.1016/j.cancergen.2020.01.001. [Epub ahead of print]

3.

Scalable Prediction of Acute Myeloid Leukemia Using High-Dimensional Machine Learning and Blood Transcriptomics.

Warnat-Herresthal S, Perrakis K, Taschler B, Becker M, Baßler K, Beyer M, Günther P, Schulte-Schrepping J, Seep L, Klee K, Ulas T, Haferlach T, Mukherjee S, Schultze JL.

iScience. 2020 Jan 24;23(1):100780. doi: 10.1016/j.isci.2019.100780. Epub 2019 Dec 18.

4.

The power and potential of integrated diagnostics in acute myeloid leukaemia.

Haferlach T, Schmidts I.

Br J Haematol. 2020 Jan;188(1):36-48. doi: 10.1111/bjh.16360. Epub 2019 Dec 6. Review.

5.

Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.

Nagata Y, Makishima H, Kerr CM, Przychodzen BP, Aly M, Goyal A, Awada H, Asad MF, Kuzmanovic T, Suzuki H, Yoshizato T, Yoshida K, Chiba K, Tanaka H, Shiraishi Y, Miyano S, Mukherjee S, LaFramboise T, Nazha A, Sekeres MA, Radivoyevitch T, Haferlach T, Ogawa S, Maciejewski JP.

Nat Commun. 2019 Nov 26;10(1):5386. doi: 10.1038/s41467-019-13001-y.

6.

The ParaHox gene Cdx4 induces acute erythroid leukemia in mice.

Thoene S, Mandal T, Vegi NM, Quintanilla-Martinez L, Rösler R, Wiese S, Metzeler KH, Herold T, Haferlach T, Döhner K, Döhner H, Schwarzmüller L, Klingmüller U, Buske C, Rawat VPS, Feuring-Buske M.

Blood Adv. 2019 Nov 26;3(22):3729-3739. doi: 10.1182/bloodadvances.2019000761.

7.

Inhibition of PLK1 by capped-dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis.

Dill V, Kauschinger J, Hauch RT, Buschhorn L, Odinius TO, Müller-Thomas C, Mishra R, Kyncl MC, Schmidt B, Prodinger PM, Hempel D, Bellos F, Höllein A, Kern W, Haferlach T, Slotta-Huspenina J, Bassermann F, Peschel C, Götze KS, Waizenegger IC, Höckendorf U, Jost PJ, Jilg S.

Eur J Haematol. 2020 Feb;104(2):125-137. doi: 10.1111/ejh.13354. Epub 2019 Dec 8.

PMID:
31758597
8.

Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations.

Höllein A, Nadarajah N, Meggendorfer M, Jeromin S, Kern W, Haferlach C, Haferlach T.

Hemasphere. 2019 Feb 4;3(1):e178. doi: 10.1097/HS9.0000000000000178. eCollection 2019 Feb.

9.

Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia.

Hartmann L, Nadarajah N, Meggendorfer M, Höllein A, Vetro C, Kern W, Haferlach T, Haferlach C, Stengel A.

Leukemia. 2019 Nov 12. doi: 10.1038/s41375-019-0633-3. [Epub ahead of print]

PMID:
31719678
10.

Cytogenetic and molecular genetic characterization of KMT2A-PTD positive acute myeloid leukemia in comparison to KMT2A-Rearranged acute myeloid leukemia.

Vetro C, Haferlach T, Meggendorfer M, Stengel A, Jeromin S, Kern W, Haferlach C.

Cancer Genet. 2020 Jan;240:15-22. doi: 10.1016/j.cancergen.2019.10.006. Epub 2019 Nov 1.

PMID:
31698332
11.

Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes.

Madan V, Li J, Zhou S, Teoh WW, Han L, Meggendorfer M, Malcovati L, Cazzola M, Ogawa S, Haferlach T, Yang H, Koeffler HP.

Am J Hematol. 2020 Feb;95(2):133-143. doi: 10.1002/ajh.25673. Epub 2019 Nov 18.

PMID:
31680297
12.

A decade with whole exome sequencing in haematology.

Hansen MC, Haferlach T, Nyvold CG.

Br J Haematol. 2020 Feb;188(3):367-382. doi: 10.1111/bjh.16249. Epub 2019 Oct 10. Review.

PMID:
31602633
13.

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis.

Jawhar M, Schwaab J, Álvarez-Twose I, Shoumariyeh K, Naumann N, Lübke J, Perkins C, Muñoz-González JI, Meggendorfer M, Kennedy V, Metzgeroth G, Fabarius A, Pfeifer D, Sotlar K, Horny HP, von Bubnoff N, Haferlach T, Cross NCP, Hofmann WK, Sperr WR, García-Montero AC, Valent P, Gotlib J, Orfao A, Reiter A.

J Clin Oncol. 2019 Nov 1;37(31):2846-2856. doi: 10.1200/JCO.19.00640. Epub 2019 Sep 11.

PMID:
31509472
14.

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA.

Parida L, Haferlach C, Rhrissorrakrai K, Utro F, Levovitz C, Kern W, Nadarajah N, Twardziok S, Hutter S, Meggendorfer M, Walter W, Baer C, Haferlach T.

PLoS Comput Biol. 2019 Aug 30;15(8):e1007332. doi: 10.1371/journal.pcbi.1007332. eCollection 2019 Aug.

15.

Molecular characterization of acute myeloid leukemia patients who relapse more than 3 years after diagnosis: an exome sequencing study of 31 patients.

Hartmann L, Haferlach C, Meggendorfer M, Nadarajah N, Kern W, Haferlach T, Stengel A.

Haematologica. 2019 Aug 1. pii: haematol.2019.227702. doi: 10.3324/haematol.2019.227702. [Epub ahead of print]

16.

Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based study.

Lauseker M, Gerlach R, Worseg W, Haferlach T, Tauscher M, Hasford J, Hoffmann VS.

Eur J Haematol. 2019 Oct;103(4):362-369. doi: 10.1111/ejh.13293. Epub 2019 Aug 28.

PMID:
31309640
17.

Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.

Iaccarino L, Ottone T, Alfonso V, Cicconi L, Divona M, Lavorgna S, Travaglini S, Ferrantini A, Falconi G, Baer C, Usai M, Forghieri F, Venditti A, Del Principe MI, Arcese W, Voso MT, Haferlach T, Lo-Coco F.

Am J Hematol. 2019 Oct;94(10):1091-1097. doi: 10.1002/ajh.25573. Epub 2019 Jul 23.

PMID:
31292998
18.

"Somatic" and "pathogenic" - is the classification strategy applicable in times of large-scale sequencing?

Baer C, Walter W, Hutter S, Twardziok S, Meggendorfer M, Kern W, Haferlach T, Haferlach C.

Haematologica. 2019 Aug;104(8):1515-1520. doi: 10.3324/haematol.2019.218917. Epub 2019 Jul 4. No abstract available.

19.

DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern.

Cappelli LV, Meggendorfer M, Dicker F, Jeromin S, Hutter S, Kern W, Haferlach T, Haferlach C, Höllein A.

Leukemia. 2019 Nov;33(11):2741-2746. doi: 10.1038/s41375-019-0502-0. Epub 2019 Jun 17. No abstract available.

PMID:
31209279
20.

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Schischlik F, Jäger R, Rosebrock F, Hug E, Schuster M, Holly R, Fuchs E, Milosevic Feenstra JD, Bogner E, Gisslinger B, Schalling M, Rumi E, Pietra D, Fischer G, Faé I, Vulliard L, Menche J, Haferlach T, Meggendorfer M, Stengel A, Bock C, Cazzola M, Gisslinger H, Kralovics R.

Blood. 2019 Jul 11;134(2):199-210. doi: 10.1182/blood.2019000519. Epub 2019 May 7.

Supplemental Content

Loading ...
Support Center